• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
On the path to translation: Highlights from the 2010 Canadian Conference on Ovarian Cancer Research.迈向转化之路:2010 年加拿大卵巢癌研究会议亮点。
J Ovarian Res. 2011 Jun 23;4:10. doi: 10.1186/1757-2215-4-10.
2
Advancing Discovery Research in Nephrology in Canada: A Conference Report From the 2021 Molecules and Mechanisms Mediating Kidney Health and Disease (M3K) Scientific Meeting and Investigator Summit.加拿大肾脏病领域探索性研究进展:2021年介导肾脏健康与疾病的分子与机制(M3K)科学会议及研究者峰会会议报告
Can J Kidney Health Dis. 2022 Dec 17;9:20543581221144824. doi: 10.1177/20543581221144824. eCollection 2022.
3
Epigenetics, eh! A meeting summary of the Canadian Conference on Epigenetics.表观遗传学,嗯!加拿大表观遗传学会议纪要。
Epigenetics. 2011 Oct 1;6(10):1265-71. doi: 10.4161/epi.6.10.17491.
4
The NCI All Ireland Cancer Conference.美国国家癌症研究所全爱尔兰癌症会议。
Oncologist. 1999;4(4):275-277.
5
The Canadian Cancer Research Conference 2019.2019 年加拿大癌症研究会议。
Curr Oncol. 2020 Apr;27(2):e226-e230. doi: 10.3747/co.27.6245. Epub 2020 May 1.
6
The inaugural Qatar Critical Care Conference with its Qatar Medical Journal Special Issue - An important milestone.首届卡塔尔重症监护会议及其《卡塔尔医学杂志》特刊——一个重要的里程碑。
Qatar Med J. 2019 Nov 7;2019(2):1. doi: 10.5339/qmj.2019.qccc.1. eCollection 2019.
7
New horizons in bladder cancer research.膀胱癌研究的新视野。
Urol Oncol. 2020 Dec;38(12):867-885. doi: 10.1016/j.urolonc.2018.12.014. Epub 2019 Mar 7.
8
The IMPAKT of breast cancer research: fundamental science and applied medicine.乳腺癌研究的影响:基础科学与应用医学
Future Sci OA. 2015 Sep 11;1(4):FSO69. doi: 10.4155/fso.15.69. eCollection 2015 Nov.
9
Fifth International Conference on Ovarian Cancer: challenges and opportunities.第五届卵巢癌国际会议:挑战与机遇
Gynecol Oncol. 2005 Jun;97(3):916-23. doi: 10.1016/j.ygyno.2005.03.013.
10
Scientific Overview on CSCI-CITAC Annual General Meeting and 2016 Young Investigators' Forum.CSCI-CITAC年度股东大会及2016年青年研究者论坛科学综述
Clin Invest Med. 2017 Oct 19;40(5):E211-E217. doi: 10.25011/cim.v40i5.28626.

引用本文的文献

1
Lin28 regulates BMP4 and functions with Oct4 to affect ovarian tumor microenvironment.Lin28 调节 BMP4,并与 Oct4 一起作用影响卵巢肿瘤微环境。
Cell Cycle. 2013 Jan 1;12(1):88-97. doi: 10.4161/cc.23028. Epub 2012 Dec 19.

本文引用的文献

1
Making the best of PARP inhibitors in ovarian cancer.最大限度地利用 PARP 抑制剂治疗卵巢癌。
Nat Rev Clin Oncol. 2010 Sep;7(9):508-19. doi: 10.1038/nrclinonc.2010.116. Epub 2010 Aug 10.
2
Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors.聚腺苷二磷酸核糖聚合酶抑制剂靶向 PTEN 突变细胞的合成致死作用。
EMBO Mol Med. 2009 Sep;1(6-7):315-22. doi: 10.1002/emmm.200900041.
3
The preclinical natural history of serous ovarian cancer: defining the target for early detection.浆液性卵巢癌的临床前自然史:确定早期检测的目标
PLoS Med. 2009 Jul;6(7):e1000114. doi: 10.1371/journal.pmed.1000114. Epub 2009 Jul 28.
4
Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers.对携带BRCA突变的肿瘤中聚(ADP - 核糖)聚合酶的抑制作用。
N Engl J Med. 2009 Jul 9;361(2):123-34. doi: 10.1056/NEJMoa0900212. Epub 2009 Jun 24.
5
Mutation of FOXL2 in granulosa-cell tumors of the ovary.卵巢颗粒细胞瘤中FOXL2的突变
N Engl J Med. 2009 Jun 25;360(26):2719-29. doi: 10.1056/NEJMoa0902542. Epub 2009 Jun 10.
6
Understanding the Warburg effect: the metabolic requirements of cell proliferation.理解瓦伯格效应:细胞增殖的代谢需求。
Science. 2009 May 22;324(5930):1029-33. doi: 10.1126/science.1160809.
7
Cancer stem cells in solid tumors: an overview.实体瘤中的癌症干细胞:综述
Semin Radiat Oncol. 2009 Apr;19(2):71-7. doi: 10.1016/j.semradonc.2008.11.001.
8
New insights into the pathogenesis of serous ovarian cancer and its clinical impact.浆液性卵巢癌发病机制的新见解及其临床影响。
J Clin Oncol. 2008 Nov 10;26(32):5284-93. doi: 10.1200/JCO.2008.18.1107. Epub 2008 Oct 14.
9
The potential of PARP inhibitors in genetic breast and ovarian cancers.聚(ADP-核糖)聚合酶抑制剂在遗传性乳腺癌和卵巢癌中的潜力。
Ann N Y Acad Sci. 2008 Sep;1138:136-45. doi: 10.1196/annals.1414.020.
10
Serous tubal intraepithelial carcinoma: its potential role in primary peritoneal serous carcinoma and serous cancer prevention.浆液性输卵管上皮内癌:其在原发性腹膜浆液性癌及浆液性癌预防中的潜在作用
J Clin Oncol. 2008 Sep 1;26(25):4160-5. doi: 10.1200/JCO.2008.16.4814.

迈向转化之路:2010 年加拿大卵巢癌研究会议亮点。

On the path to translation: Highlights from the 2010 Canadian Conference on Ovarian Cancer Research.

机构信息

London Regional Cancer Program, 790 Commissioners Road East, London, ON, Canada.

出版信息

J Ovarian Res. 2011 Jun 23;4:10. doi: 10.1186/1757-2215-4-10.

DOI:10.1186/1757-2215-4-10
PMID:21699706
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3138423/
Abstract

Ovarian cancer continues to be the most lethal of the gynaecologic malignancies due to the lack of early detection, screening strategies and ineffective therapeutics for late-stage metastatic disease, particularly in the recurrent setting. The gathering of researchers investigating fundamental pathobiology of ovarian cancer and the clinicians who treat patients with this insidious disease is paramount to meeting the challenges we face. Since 2002, the Canadian Conference on Ovarian Cancer Research, held every two years, has served this essential purpose. The objectives of this conference have been to disseminate new information arising from the most recent ovarian cancer research and identify the most pressing challenges we still face as scientists and clinicians. This is best accomplished through direct encounters and exchanges of innovative ideas among colleagues and trainees from the realms of basic science and clinical disciplines. This meeting has and continues to successfully facilitate rapid networking and establish new collaborations from across Canada. This year, more guest speakers and participants from other countries have extended the breadth of the research on ovarian cancer that was discussed at the meeting. This report summarizes the key findings presented at the fifth biennial Canadian Conference on Ovarian Cancer Research held in Toronto, Ontario, and includes the important issues and challenges we still face in the years ahead to make a significant impact on this devastating disease.

摘要

由于缺乏早期检测、筛查策略以及晚期转移性疾病(特别是在复发情况下)的有效治疗方法,卵巢癌仍然是妇科恶性肿瘤中最致命的一种。研究卵巢癌基础病理生物学的研究人员和治疗这种隐匿性疾病的临床医生的聚集,对于应对我们所面临的挑战至关重要。自 2002 年以来,每两年举办一次的加拿大卵巢癌研究会议就发挥了这一重要作用。该会议的目标是传播最新卵巢癌研究产生的新信息,并确定我们作为科学家和临床医生仍然面临的最紧迫挑战。这是通过基础科学和临床学科领域的同事和学员之间的直接交流和创新思想的交流来实现的。该会议已经并将继续成功促进加拿大各地的快速网络建立和新的合作。今年,更多来自其他国家的特邀演讲者和参与者扩大了会议讨论的卵巢癌研究范围。本报告总结了在安大略省多伦多举行的第五届两年一次的加拿大卵巢癌研究会议上提出的主要发现,并包括了我们在未来几年中仍然面临的重要问题和挑战,以对这种毁灭性疾病产生重大影响。